

THE CLAIMS

What is claimed is:

1. A method of treating or preventing asthma or
5 the symptoms thereof in a human which comprises administering
to a human a therapeutically effective amount of
norastemizole, or a pharmaceutically acceptable salt thereof,
and a therapeutically effective amount of a leukotriene
inhibitor, or a pharmaceutically acceptable salt thereof.

10

2. A method of treating or preventing asthma or
the symptoms thereof in a human which comprises administering
to a human a composition, said composition comprising (i) a
therapeutically effective amount of norastemizole, or a
15 pharmaceutically acceptable salt thereof; (ii) a
therapeutically effective amount of leukotriene inhibitor, or
a pharmaceutically acceptable salt thereof, selected from the
group consisting of 5-lipoxygenase inhibitors, 5-lipoxygenase
activating protein antagonists, leukotriene receptor
20 antagonists, and mixtures thereof; and a pharmaceutically
acceptable carrier or excipient.

3. The method of claim 1, wherein the
administration of the amount norastemizole, or a
25 pharmaceutically acceptable salt thereof, and the amount of
leukotriene inhibitor, or a pharmaceutically acceptable salt
thereof, avoids the concomitant liability of adverse effects
associated with the administration of non-sedating
antihistamines.

30

4. The method of claim 2, wherein the
administration of the amount norastemizole, or a
pharmaceutically acceptable salt thereof, and the amount of
leukotriene inhibitor, or a pharmaceutically acceptable salt
35 thereof, avoids the concomitant liability of adverse effects
associated with the administration of non-sedating
antihistamines.

5. The method of claim 1, 2, 3, or 4 wherein the administering further comprises a therapeutically effective amount of a decongestant, or a pharmaceutically acceptable salt thereof.

5

6. The method of claim 1 wherein said human has asthma.

7. A method of treating or preventing dermatitis
10 in a human which comprises administering to a human a therapeutically effective amount of norastemizole, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof.

15

8. A method of treating or preventing dermatitis in a human which comprises administering to a human a composition, said composition comprising (i) a therapeutically effective amount of norastemizole, or a
20 pharmaceutically acceptable salt thereof; (ii) a therapeutically effective amount of leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, selected from the group consisting of 5-lipoxygenase inhibitors, 5-lipoxygenase activating protein antagonists, leukotriene receptor
25 antagonists, and mixtures thereof; and a pharmaceutically acceptable carrier or excipient.

9. The method of claim 7 wherein the administration of the amount norastemizole, or a
30 pharmaceutically acceptable salt thereof, and the amount of leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, avoids the concomitant liability of adverse effects associated with the administration of non-sedating antihistamines.

35

10. The method of claim 8 wherein the administration of the amount norastemizole, or a

pharmaceutically acceptable salt thereof, and the amount of leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, avoids the concomitant liability of adverse effects associated with the administration of non-sedating
5 antihistamines.

11. The method of claim 7, 8, 9, or 10 wherein the administering further comprises a therapeutically effective amount of a decongestant, or a pharmaceutically acceptable
10 salt thereof.

12. A method of treating or preventing allergic rhinitis in a human which comprises administering to a human a therapeutically effective amount of norastemizole, or a
15 pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof.

13. A method of treating or preventing allergic
20 rhinitis in a human which comprises administering to a human a composition, said composition comprising (i) a therapeutically effective amount of norastemizole, or a pharmaceutically acceptable salt thereof; (ii) a therapeutically effective amount of leukotriene inhibitor, or
25 a pharmaceutically acceptable salt thereof, selected from the group consisting of 5-lipoxygenase inhibitors, 5-lipoxygenase activating protein antagonists, leukotriene receptor antagonists, and mixtures thereof; and a pharmaceutically acceptable carrier or excipient.

30
14. The method of claim 12 wherein the administration of the amount norastemizole, or a pharmaceutically acceptable salt thereof, and the amount of leukotriene inhibitor, or a pharmaceutically acceptable salt
35 thereof, avoids the concomitant liability of adverse effects associated with the administration of non-sedating antihistamines.

15. The method of claim 13, wherein the administration of the amount norastemizole, or a pharmaceutically acceptable salt thereof, and the amount of leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, avoids the concomitant liability of adverse effects associated with the administration of non-sedating antihistamines.

16. The method of claim 12, 13, 14, or 15 wherein the administering further comprises a therapeutically effective amount of a decongestant, or a pharmaceutically acceptable salt thereof.

17. A method of treating or preventing inflammation in a human which comprises administering to a human a therapeutically effective amount of norastemizole, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof.

18. A method of treating or preventing inflammation in a human which comprises administering to a human a composition, said composition comprising (i) a therapeutically effective amount of norastemizole, or a pharmaceutically acceptable salt thereof; (ii) a therapeutically effective amount of leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, selected from the group consisting of 5-lipoxygenase inhibitors, 5-lipoxygenase activating protein antagonists, leukotriene receptor antagonists, and mixtures thereof; and a pharmaceutically acceptable carrier or excipient.

19. The method of claim 17 wherein the administration of the amount norastemizole, or a pharmaceutically acceptable salt thereof, and the amount of leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, avoids the concomitant liability of adverse effects

associated with the administration of non-sedating antihistamines.

20. The method of claim 18, wherein the
5 administration of the amount norastemizole, or a
pharmaceutically acceptable salt thereof, and the amount of
leukotriene inhibitor, or a pharmaceutically acceptable salt
thereof, avoids the concomitant liability of adverse effects
associated with the administration of non-sedating
10 antihistamines.

21. The method of claim 17, 18, 19, or 20 wherein
the administering further comprises a therapeutically
effective amount of a decongestant, or a pharmaceutically
15 acceptable salt thereof.

22. A method for treating or preventing a
condition responsive to leukotriene inhibition which
comprises administering a therapeutically effective amount of
20 norastemizole, or a pharmaceutically acceptable salt thereof,
and a therapeutically effective amount of a leukotriene
inhibitor, or a pharmaceutically acceptable salt thereof.

23. A method of treating or preventing a condition
25 responsive to leukotriene inhibition which comprises
administering to a human a composition, said composition
comprising (i) a therapeutically effective amount of
norastemizole, or a pharmaceutically acceptable salt thereof;
(ii) a therapeutically effective amount of leukotriene
30 inhibitor, or a pharmaceutically acceptable salt thereof,
selected from the group consisting of 5-lipoxygenase
inhibitors, 5-lipoxygenase activating protein antagonists,
leukotriene receptor antagonists, and mixtures thereof; and
(iii) a pharmaceutically acceptable carrier or excipient.
35

24. The method of claim 22 wherein the
administration of the amount norastemizole, or a

pharmaceutically acceptable salt thereof, and the amount of leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, avoids the concomitant liability of adverse effects associated with the administration of non-sedating

5 antihistamines.

25. The method of claim 23, wherein the administration of the amount norastemizole, or a pharmaceutically acceptable salt thereof, and the amount of
10 leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, avoids the concomitant liability of adverse effects associated with the administration of non-sedating antihistamines.

15 26. The method of claim 22, 23, 24, or 25 wherein the administering further comprises a therapeutically effective amount of a decongestant, or a pharmaceutically acceptable salt thereof.

20 27. The method of claim 22 wherein the condition responsive to leukotriene inhibition comprises asthma or a symptom thereof.

28. The method of claim 22 wherein the condition
25 responsive to leukotriene inhibition comprises an allergic condition.

29. The method of claim 22 wherein the condition responsive to leukotriene inhibition comprises inflammation.
30

30. The method of claim 1, 2, 7, 8, 12, 13, 17, 18, 22, or 23 wherein the amount of norastemizole administered is from about 1 mg to about 200 mg per day.

35 31. The method of claim 30 wherein the amount of norastemizole administered is from about 10 mg to about 100 mg per day.

32. The method of claim 1, 2, 7, 8, 12, 13, 17, 18, 22, or 23 wherein the compositions are administered as a nasal or oral spray.

5 33. The method of claim 1, 2, 7, 8, 12, 13, 17, 18, 22, or 23 wherein at least one of the norastemizole and the leukotriene inhibitor is administered as a nasal or oral spray.

10 34. The method of claim 1, 2, 7, 8, 12, 13, 17, 18, 22, or 23 wherein at least one of the norastemizole and the leukotriene inhibitor is administered in an oral solid dosage form.

15 35. The method of claim 3, 9, 14, 19, or 24 wherein the norastemizole is administered as a nasal or oral spray.

20 36. The method of claim 1, 2, 7, 8, 12, 13, 17, 18, 22, or 23 wherein the leukotriene inhibitor is a 5-lipoxygenase inhibitor.

25 37. The method of claim 36, wherein the 5-lipoxygenase inhibitor is selected from the group consisting of zileuton, docebenone, piripost, ICI-D2318, and mixtures thereof.

30 38. The method of claim 1, 2, 7, 8, 12, 13, 17, 18, 22, or 23 wherein the leukotriene inhibitor is a 5-lipoxygenase activating protein.

35 39. The method of claim 38, wherein the 5-lipoxygenase activating protein is selected from the group consisting of MK-591, MK-886, and mixtures thereof.

40. The method of claim 1, 2, 7, 8, 12, 13, 17, 18, 22, or 23 wherein the leukotriene inhibitor is a leukotriene receptor antagonist.

5 41. The method of claim 40, wherein the leukotriene receptor antagonist is selected from the group consisting of zafirlukast, montelukast, pranlukast, sodium 1-(((R)-(3-(2-(6,7-difluoro-2-quinolinyl)ethynyl)phenyl)-3-(2-(2-hydroxy-2-propyl)phenyl)thio)methyl)cyclopropaneacetate;
10 1-(((1(R)-(3-(2-(2,3-dichlorothiopheno[3,2-b]pyridin-5-yl)-(E)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid, and salts and mixtures thereof.

15 42. A pharmaceutical composition which comprises a therapeutically effective amount of norastemizole, or a pharmaceutically acceptable salt thereof; a therapeutically effective amount of a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof; and a
20 pharmaceutically acceptable carrier or excipient.

43. The pharmaceutical composition of claim 42 which further comprises a therapeutically effective amount of a decongestant, or a pharmaceutically acceptable salt
25 thereof.

44. A pharmaceutical composition which comprises from about 1 mg to about 200 mg of norastemizole, or a pharmaceutically acceptable salt thereof, and from about 20
30 mg to about 2,500 mg of 5-lipoxygenase inhibitor, or a pharmaceutically acceptable salt thereof.

45. A pharmaceutical composition which comprises from about 1 mg to about 200 mg of norastemizole, or a
35 pharmaceutically acceptable salt thereof, and from about 20 mg to about 2500 mg of 5-lipoxygenase activating protein antagonist, or a pharmaceutically acceptable salt thereof.

46. A pharmaceutical composition which comprises from about 1 mg to about 200 mg of norastemizole, or a pharmaceutically acceptable salt thereof, and from about 2 mg to about 200 mg of leukotriene receptor antagonist, or a pharmaceutically acceptable salt thereof.

47. The composition of claim 42, 43, 44, 45, or 46 administered as a nasal or oral spray.

48. The composition of claim 42, 43, 44, 45, or 46 wherein at least one of the norastemizole and the leukotriene inhibitor is administered as a nasal or oral spray.

49. The composition of claim 42, 43, 44, 45, or 46 wherein at least one of the norastemizole and the leukotriene inhibitor is administered in an oral solid dosage form.